Meclizine moderates lipopolysaccharide-induced neuroinflammation in mice through the regulation of AKT/ NF-κβ/ERK/JNK signaling pathway.

"Declarations Conflicts of interest/Competing interestsThe authors have no conflicts of interest to declare that are relevant to the content of this article. Ethics approvalThe study was conducted following the recommendations of the Helsinki Declaration, good medical and laboratory practices (GCP and GLP). National Research Centre–Medical Research Ethics Committee (NRC-MREC) for the use of animal subjects granted ethical approval for the current study (Approval number 1414052023). Consent to participateNot applicable. Consent for publicationNot applicable. Conflicts of interest/Competing interests The authors have no conflicts of interest to declare that are relevant to the content of this article."

"Funding The authors have no relevant financial or non-financial interests to disclose. Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB)."